Cochrane · systematic review · CD012990
GLP‐1 receptor agonists for Parkinson's disease
Mulvaney, CA, Duarte, GS, Handley, J, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
7
No studies
1
Included studies
NR
No studies 1 · 12.5%Ungraded 0 · 0%Very low 4 · 50%Low 3 · 37.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
GLP‐1 receptor agonists compared to placebo for adults with Parkinson's disease
Population: adults with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PD motor impairment GLP‐1 receptor agonists vs placebo | no estimate extracted | 1 study · 60 participants | Low Downgraded: indirectness |
HRQoL GLP‐1 receptor agonists vs placebo | no estimate extracted | 1 study · 60 participants | Low Downgraded: indirectness |
Serious adverse events GLP‐1 receptor agonists vs placebo | no estimate extracted | NR | No studies |
Adverse events ‐ weight loss GLP‐1 receptor agonists vs placebo | RR 1.25 [0.89, 1.76] | 1 study · 60 participants | Low Downgraded: indirectness |
GLP‐1 receptor agonists compared to no treatment for adults with Parkinson's disease
Population: adults with Parkinson's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PD motor impairment GLP‐1 receptor agonists vs no treatment | no estimate extracted | 1 study · 44 participants | Very low Downgraded: risk of bias |
HRQoL GLP‐1 receptor agonists vs no treatment | no estimate extracted | 1 study · 44 participants | Very low Downgraded: risk of bias |
Serious adverse events. GLP‐1 receptor agonists vs no treatment | RR 1.6 [0.4, 6.32] | 1 study · 44 participants | Very low Downgraded: risk of bias |
Adverse events ‐ weight loss GLP‐1 receptor agonists vs no treatment | no estimate extracted | 1 study · 44 participants | Very low Downgraded: risk of bias |